Treatment of immune disease by mucosal delivery of antigens using genetically modified Lactococcus
The present invention relates to the treatment of autoimmune and allergic diseases by mucosal delivery by micro-organism, in particular Lactococcus lactis , of secreted immunodominant antigens.
1. A method for treating an allergy in a subject in need thereof, the method comprising:
orally administering to the subject a composition comprising lactic acid bacteria comprising a nucleic acid sequence integrated into a chromosome of the lactic acid bacteria and encoding an antigen involved in the induction of the allergy in the subject,
wherein the antigen is constitutively expressed by the lactic acid bacteria,
wherein the antigen is selected from the group consisting of a tree pollen allergen, a grass pollen allergen, a weed pollen allergen, a dust allergen, a dust mite allergen, a mold allergen, and an animal dander allergen, and
wherein said administering induces an antigen specific immune tolerance in the subject.
2. The method according to claim 1 , wherein the allergy is an allergic reaction or allergic asthma.
3. The method according to claim 1 , wherein the lactic acid bacteria are Lactococcus lactis.
4. The method according to claim 1 , wherein the method results in the induction of regulatory T-cells (Treg cells) in the subject.
5. The method according to claim 4 , wherein the Treg cells are Foxp3 + .
6. The method according to claim 1 , wherein the antigen reduces the proliferation of spleen and inguinal lymph node cells.
7. The method according to claim 1 , wherein the antigen suppresses an inflammatory antigen specific T-cell response.
8. The method according to claim 1 , wherein the composition is administered to the subject daily for at least 1 week.
9. The method according to claim 1 , wherein the composition is administered to the subject at least once a day.
10. The method according to claim 1 , wherein the composition is administered to the subject at least twice a day.
11. The method according to claim 1 , wherein the lactic acid bacteria are administered at a dose of at least 10 femtograms to 100 mg daily.
12. The method according to claim 1 , wherein the composition is orally administered as a capsule, lozenge, tablet, suspension, emulsion, or troche.
13. The method according to claim 1 , wherein the composition is formulated as a medicament, medical food, or a nutraceutical.
14. The method according to claim 1 , wherein a single dose of the composition comprises at least 10 femtograms of the lactic acid bacteria.
15. The method according to claim 1 , wherein the allergen is a Der p1 peptide.
16. A method for treating an allergy in a subject in need thereof, the method comprising:
mucosally administering to the subject a composition comprising lactic acid bacteria expressing an antigen involved in the induction of the allergy in the subject,
wherein the antigen is constitutively secreted by the lactic acid bacteria, and wherein the antigen is an animal dander allergen or a dust mite allergen and,
wherein said administering induces an antigen specific immune tolerance in the subject.
17. The method according to claim 16 , wherein the antigen is a Der p1 peptide.
18. The method according to claim 16 , wherein the composition is administered to the subject at least once a day for at least 1 week.
19. The method according to claim 16 , wherein the lactic acid bacteria are bacterium is a Lactococcus species.
20. The method according to claim 19 , wherein the Lactococcus species is Lactococcus lactis.
21. The method according to claim 16 , wherein the method results in the induction of regulatory T-cells (Treg cells) in the subject.
22. The method according to claim 1 , wherein the lactic acid bacteria are a Lactococcus species.
23. The method according to claim 1 , wherein the antigen is constitutively secreted by the lactic acid bacteria or is displayed at a cell surface of the lactic acid bacteria.
24. The method according to claim 1 , wherein the nucleic acid sequence encoding the antigen further comprises a secretory signal sequence.
25. The method according to claim 1 , wherein the secretory signal sequence is a Usp45 secretion signal.
26. The method of claim 1 , wherein the subject is a human.
27. The method of claim 1 , wherein the composition is an oral dosage form selected from a tablet and a capsule.
28. The method of claim 1 , wherein the composition is a medical food or nutraceutical.
29. The method of claim 16 , wherein the subject is a human.
30. A method for treating an allergy in a subject in need thereof, the method comprising:
orally administering to the subject lactic acid bacteria comprising a nucleic acid sequence encoding an antigen involved in the induction of the allergy in the subject,
wherein the nucleic acid sequence is integrated into a chromosome of the lactic acid bacteria,
wherein the antigen is constitutively expressed and secreted by the lactic acid bacteria,
wherein the antigen is selected from the group consisting of a tree pollen allergen, a grass pollen allergen, a weed pollen allergen, a dust allergen, a dust mite allergen, a mold allergen, and an animal dander allergen, and
wherein said administering induces an antigen specific immune tolerance in the subject.
31. The method of claim 30 , wherein the subject is a human.
32. A method for treating an allergy in a subject in need thereof, the method comprising:
orally administering to the subject a composition comprising lactic acid bacteria comprising a nucleic acid sequence encoding an antigen involved in the induction of the allergy in the subject,
wherein the antigen is constitutively expressed by the lactic acid bacteria,
wherein the antigen is a dust mite allergen Der pi peptide, and
wherein said administering induces an antigen specific immune tolerance in the subject.
33. The method of claim 32 , wherein the subject is a human.